Alnylam Pharma (ALNY) Tops Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Alnylam Pharma (ALNY) Tops Q1 EPS by 1c

Alnylam Pharmaceuticals (ALNY) PT Trimmed to $95 at Chardan Capital Markets

May 5, 2017 10:07 AM EDT

Chardan Capital Markets lowered its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $95.00 (from $97.00) while maintaining a Buy rating following Q1 results.

Analyst Madhu Kumar commented, "Alnylam's lead asset, patisiran, a RNAi drug targeting transthyretin (TTR), is currently in the phase III APOLLO... More